Quick Answer
Phio Pharmaceuticals Corp. reported Total Revenue of $0.00 for fiscal year 2020.
Phio Pharmaceuticals Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $0.00 -100.0% |
| Net Income | -$8.70M -21.7% |
-$7.15M +34.0% |
-$10.83M +5.7% |
-$11.48M +13.6% |
-$13.29M -51.1% |
-$8.79M +1.3% |
| Diluted EPS | — | -$9.08 +80.6% |
-$46.76 -363.0% |
-$10.10 +18.7% |
-$12.43 | — |
| Total Assets | $21.49M +274.5% |
$5.74M -38.7% |
$9.36M -26.9% |
$12.81M -49.1% |
$25.17M +59.9% |
$15.74M +95.8% |
| Cash and Equivalents | $21.03M +290.8% |
$5.38M -36.6% |
$8.49M | — | — | — |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$231.0K |
| Stockholders Equity | $20.15M +326.6% |
$4.72M -38.9% |
$7.73M -28.7% |
$10.84M -50.6% |
$21.93M +68.5% |
$13.02M +126.5% |
| R&D Expense | $4.62M +26.8% |
$3.64M -42.5% |
$6.33M -9.7% |
$7.01M -21.1% |
$8.89M +139.1% |
$3.72M -13.6% |
| Operating Income | -$9.22M -24.8% |
-$7.39M +31.8% |
-$10.82M +5.6% |
-$11.46M +15.2% |
-$13.51M -53.7% |
-$8.79M +2.2% |
| Shares Outstanding | 11.62M +570.1% |
1.73M +316.4% |
416,368 -63.4% |
1.14M +1.0% |
1.13M -80.5% |
5.78M +763.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2020 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$2.39M | -57.0% | -10.4% |
| Diluted EPS | June 30, 2025 | -$0.45 | +87.6% | -9.8% |
| Total Assets | September 30, 2025 | $11.51M | +96.2% | +1.8% |
| Cash and Equivalents | September 30, 2025 | $10.71M | +98.6% | -0.6% |
| Long-Term Debt | September 30, 2021 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $9.84M | +98.9% | -2.5% |
| R&D Expense | September 30, 2025 | $1.18M | +83.4% | +10.0% |
| Operating Income | September 30, 2025 | -$2.50M | -57.5% | -8.5% |
| Shares Outstanding | September 30, 2025 | 5.78M | +503.7% | +20.6% |
- Phio Pharmaceuticals Corp. reported Total Revenue of $0.00 for fiscal year 2020.
- Phio Pharmaceuticals Corp. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Net Income of -$8.70 million for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed a decrease of -21.7% in Net Income compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Diluted EPS of $9.08 per share (loss) for fiscal year 2024.
- Phio Pharmaceuticals Corp. showed an increase of +80.6% in Diluted EPS compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Total Assets of $21.49 million for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed an increase of +274.5% in Total Assets compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Cash and Equivalents of $21.03 million for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed an increase of +290.8% in Cash and Equivalents compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Long-Term Debt of $0.00 for fiscal year 2021.
- Phio Pharmaceuticals Corp. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Stockholders Equity of $20.15 million for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed an increase of +326.6% in Stockholders Equity compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported R&D Expense of $4.62 million for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed an increase of +26.8% in R&D Expense compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Operating Income of -$9.22 million for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed a decrease of -24.8% in Operating Income compared to the prior fiscal year.
- Phio Pharmaceuticals Corp. reported Shares Outstanding of 11.62 million shares for fiscal year 2025.
- Phio Pharmaceuticals Corp. showed an increase of +570.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: